Twist Bioscience Corp [TWST] stock is trading at $28.84, up 0.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TWST shares have gain 15.36% over the last week, with a monthly amount drifted -21.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Twist Bioscience Corp [NASDAQ: TWST] stock has seen the most recent analyst activity on December 13, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $60. Previously, Guggenheim started tracking the stock with Buy rating on June 04, 2024, and set its price target to $53. On January 17, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $45 on the stock. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $27 on September 27, 2023. Scotiabank initiated its recommendation with a Sector Outperform and recommended $33 as its price target on January 05, 2023. Evercore ISI upgraded its rating to Outperform for this stock on January 03, 2023, and upped its price target to $36.
Twist Bioscience Corp [TWST] stock has fluctuated between $24.28 and $55.33 over the past year. Currently, Wall Street analysts expect the stock to reach $46.67 within the next 12 months. Twist Bioscience Corp [NASDAQ: TWST] shares were valued at $28.84 at the most recent close of the market. An investor can expect a potential return of 61.82% based on the average TWST price forecast.
Analyzing the TWST fundamentals
Twist Bioscience Corp [NASDAQ:TWST] reported sales of 362.27M for the trailing twelve months, which represents a growth of 17.91%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -0.39%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.18 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.06 points at the first support level, and at 27.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.67, and for the 2nd resistance point, it is at 30.49.
Ratios To Look Out For
For context, Twist Bioscience Corp’s Current Ratio is 3.90. As well, the Quick Ratio is 3.60, while the Cash Ratio is 2.31. Considering the valuation of this stock, the price to sales ratio is 4.81, the price to book ratio is 3.63.
Transactions by insiders
Recent insider trading involved WERNER ROBERT F., Chief Accounting Officer, that happened on Aug 04 ’25 when 186.0 shares were sold. Chief Executive Officer, Leproust Emily M. completed a deal on Aug 04 ’25 to sell 5585.0 shares. Meanwhile, SVP of Human Resources Green Paula sold 1255.0 shares on Aug 04 ’25.
